Clinical Trials Logo

Clinical Trial Summary

This study will evaluate children with mastocytosis, a disease of excessive mast cells in tissues such as skin and bone marrow, to identify the cause of the disease and describe its course. Mast cells can release chemicals that cause itching, blisters, flushing, bone pain, and abdominal pain. Usually, mastocytosis in children involves the skin only and is of limited duration. This study, however, will focus on children with more severe disease that more closely resembles adult-onset mastocytosis.

Patients up to 21 years of age with childhood-onset mastocytosis may be eligible for this study. Candidates must have one or more of the following abnormalities, which indicate severe disease: enlarged liver or spleen; diffuse skin involvement; history of gastrointestinal bleeding or peptic ulcer; bone marrow biopsy with abnormal mast cells either in number or shape; elevated blood levels of the enzyme tryptase; or abnormal hemoglobin, white blood cells, platelets, or clotting factors.

Participants will have a medical history and physical examination; various blood tests, including studies to identify genetic changes that are important in the growth, development, and functioning of human mast cells; and bone marrow aspiration and biopsy. For the bone marrow procedure, the skin over the hipbone and the outer surface of the bone itself are numbed with an injection of local anesthesia. Then, a special needle is inserted into the hipbone and about 2 tablespoons of bone marrow are drawn into a syringe. Another needle is then inserted through the first needle to collect a small piece of the bone marrow. Pain will be managed according to the individual patient s needs. Additional procedures, such as a gastroenterology consultation, colonoscopy to examine the colon, or computerized axial tomography (CT) or ultrasound of the abdomen to assess the liver and spleen, may be done if medically indicated. Standard medical treatment, including antihistamines for itching or steroids for abdominal cramping or diarrhea, will be recommended as appropriate.

Patients biologic parents may also be enrolled to provide a blood sample for genetic analysis and a bone marrow aspirate and biopsy for clinical and research purposes.

Patients will return to NIH once a year for follow-up evaluations until their disease is stable or until the 5-year study ends.

...


Clinical Trial Description

Mastocytosis in infants and children is an unusual disease characterized by an excess of mast cells in tissues. In pediatric onset mastocytosis, disease is usually localized to the skin and disease is considered to be of limited duration. However, a subset of children appear to develop a clinical picture resembling that observed in adults who have adult-onset disease. This study will focus on children with more severe mastocytosis in an attempt to define its pathogenesis, focusing on mutations and polymorphisms in genes regulating mast cell proliferation and survival to determine if they might contribute to this disease pattern. If severe pediatric-onset disease does not fit within the existing classification, new criteria of diagnosis must be proposed for the pediatric age group.

This study will examine children and young adults age birth to 21 years with pediatric-onset disease previously enrolled on NIAID mastocytosis protocols, or as a result of physician referral, which have disease more consistent with adult-onset disease or parameters associated with increased morbidity. The evaluation may include serum tryptase, blood count, bone marrow biopsy and aspirate, morphology and mutational analysis. Subjects may be asked to return in 12-24 months for assessment. If relevant mutation effecting mast cell growth and function are identified, such mutations will be sought in the biologic parents as appropriate, but only when such mutations are believed to be germ line (not somatic) mutations. This study will aid in the understanding of the characteristics of severe mastocytosis in the pediatric age group. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00050193
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase
Start date November 22, 2002
Completion date March 10, 2014

See also
  Status Clinical Trial Phase
Completed NCT01333293 - The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients Phase 2/Phase 3
Completed NCT01481909 - Study on Mastocytosis for Rupatadine Treatment Phase 2/Phase 3
Recruiting NCT00044122 - Study of Factors Regulating Mast Cell Proliferation
Recruiting NCT06440148 - Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis
Recruiting NCT03340155 - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases N/A
Not yet recruiting NCT05084872 - Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients Phase 2/Phase 3
Terminated NCT01701843 - Cromoglicate in Mastocytosis Phase 2
Completed NCT00831974 - Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis Phase 2
Completed NCT00047918 - Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing N/A
Completed NCT00006413 - Stem Cell Transplantation to Treat Systemic Mastocytosis Phase 2
Completed NCT02620254 - Mast Cell Connect: A Registry for Patients With Mastocytosis
Completed NCT00255346 - Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Phase 2
Completed NCT00001356 - Characteristics of Mast Cells in Mastocytosis N/A
Recruiting NCT06466889 - Mastocytosis Registry (of Zurich)
Recruiting NCT05186753 - (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis Phase 2
Completed NCT02478957 - Treatment of Indolent Systemic Mastocytosis With PA101 Phase 2
Recruiting NCT02450396 - Pregnancy and Medically Assisted Conception in Rare Diseases
Completed NCT00038675 - Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate N/A
Not yet recruiting NCT06432556 - Study of Cellular Heterogeneity in Patients With Mastocytosis N/A
Completed NCT00336076 - Molecular Mechanisms and Diagnosis of Mastocytosis N/A